Lipogems International, the Italian biotech specialized in the sector of regenerative medicine and medical technologies for the processing of adipose tissue, announces that the enrollment of patients in the Attic clinical trial has been completed, the Italian multicenter study for the treatment of the most severe complication of Crohn’s disease, complex perianal fistula.
New path in the treatment of patients suffering from Crohn’s disease
Lipogems International has already defined a new standard of care in orthopaedics, in particular in the conservative therapy of osteoarthritis, a market worth approximately 7 billion dollars in the USA alone, and is preparing, with the achievement of this goal, to open a new road in the treatment of patients affected by Crohn’s disease, which number approximately 2.5 million (in the USA, EU and Japan), of which approximately 1 million develop perianal fistulas of varying degrees. The clinical, social and economic impact of these complications produces considerable physical and psychological suffering in patients and has a significant impact on healthcare costs, with a dimension reaching approximately 16 billion dollars per year.
Objective: to extend the use of the Lipogems device to all possible applications
The results of the Attic study, expected by the end of 2024, on the efficacy and safety of microfragmented adipose tissue, will allow Lipogems to become an alternative therapy to the current standard. «Our goal is to extend the use of the Lipogems device to all possible applications, in order to improve the quality of life of patients suffering from pathologies which, to date, have no effective treatment prospects. The results expected from the Attic study will be a further confirmation of the excellence of the Italian industry in the medical field”, declared Giorgio Ninzoli, CEO of the company established in 2012 by Professor Camillo Ricordi, director of the Diabetes Research Institute of Miami and by Professor Carlo Tremolada, plastic surgeon, and who is now present in over 28 countries around the world, with over 60,000 patients treated and over 120 scientific publications. (All rights reserved)
Posting time: 06/06/2024 08:46
Last update: 06/06/2024 15:17
